Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei
Sponsor: Kartos Therapeutics, Inc.
Check if you qualify for this myelofibrosis clinical trial in Chicago, IL
If you're searching for myelofibrosis treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.